Investors Alert: Key Updates on Semler Scientific
NEW YORK — Pomerantz LLP is actively informing investors about a class action lawsuit filed against Semler Scientific, Inc. (NASDAQ: SMLR). If you have suffered losses on your investments in Semler, it’s essential to be aware of this opportunity and the ensuing deadlines.
Who Should Be Informed?
Investors who acquired Semler securities during the Class Period are especially urged to get in touch with Danielle Peyton for more information. These individuals may have a chance to act as Lead Plaintiff in the class action. Whenever you reach out via email, it is beneficial to include your contact details and the number of shares you purchased.
Understanding the Class Action
This class action encompasses potential securities fraud and unlawful business practices allegedly committed by Semler and its executives. If you suspect you've been impacted, you have until October 28, 2025, to formally request to be appointed as Lead Plaintiff.
Significant Developments
On February 28, 2025, Semler disclosed that there are risks associated with possible allegations arising from the U.S. Department of Justice (DOJ). The company indicated that it received an initial civil investigative demand regarding its QuantaFlo device claims from the DOJ back in 2017.
Impact on Stock Price
After this disclosure, Semler's stock saw a substantial decline of $4.03 per share, representing a drop of 9.4%, closing at $38.89. This significant shift in stock value prompted concern among investors.
Settlement Agreements and Subsequent Developments
On April 15, 2025, the company announced that it had reached a preliminary agreement with the DOJ for a settlement of $29.75 million, which stirred additional stock fluctuations. The immediate aftermath saw a decline of $3.40 per share, leading to a closing price of $31.00.
Who Are Pomerantz LLP?
Pomerantz LLP is recognized for its efforts in corporate, securities, and antitrust class-action litigation, with a robust history dating back over 85 years. The firm has a strong commitment to protecting the rights of investors who have fallen victim to potential financial misconduct, securities fraud, or breaches of fiduciary duty. They have successfully recovered significant damages for countless class members over the years.
Contact Information for Investors
For any inquiries regarding the lawsuit or if you believe you qualify as a member of the class, it is advisable to contact Danielle Peyton at Pomerantz LLP. With direct lines available, prospective plaintiffs can receive guidance to navigate the complexities of the legal process.
Contact:
Danielle Peyton
Pomerantz LLP
646-581-9980 ext. 7980
Frequently Asked Questions
What is the class action lawsuit against Semler Scientific about?
The lawsuit focuses on allegations of securities fraud and unlawful practices by Semler and its officers, impacting investors who purchased their stock.
How can I participate in the class action?
Investors must contact Pomerantz LLP before the deadline to request to be appointed as the Lead Plaintiff, providing their investment details.
What are the recent significant events related to Semler?
Semler faced scrutiny from the DOJ regarding its reimbursement claims and recently announced a substantial settlement involving claims against it.
What was the impact on Semler's stock price?
The company experienced notable stock price declines following the announcements related to investigations by the DOJ and subsequent settlement agreements.
Who can I contact for more information?
Investors may reach out to Danielle Peyton at Pomerantz LLP for further assistance and clarity on their potential involvement in the class action.
